In Reply We thank Mark et al for their comments regarding our work on statin prescription decision support embedded within the electronic health record.1 We appreciate their interest and the perspective they have added, particularly regarding the important topic of statin intolerance and resistance.
We agree that the evidence base for the prescription of statin therapy for primary and secondary prevention of cardiovascular disease is robust, as is the one illustrating gaps and inequities in guideline-directed statin prescription.2 These gaps can also be exacerbated by the cognitive constraints, biases, and motivation of health care professionals and patients, even throughout the same clinic day, as exemplified by a decrease in new statin prescriptions as a clinic day progresses.3 This calls for the creation, testing, and implementation of multifaceted clinician-focused, patient-focused, and system-focused behavioral strategies aimed at overcoming inertia to initiating and maintaining statin therapy in appropriate patients.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Adusumalli S, Patel MS. Statin Prescribing and Dosing—Failure Has Become an Option—Reply. JAMA Cardiol. 2021;6(7):855. doi:10.1001/jamacardio.2021.0838
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.